An overview of the innate and adaptive immune system in inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 23, Issue 1, 2017, Pages 2-13

  Choy, Matthew C ^a,b,c   Visvanathan, Kumar ^c   De Cruz, Peter ^a,c  

^a AUSTIN HOSPITAL   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

adaptive; immune system; inflammatory bowel disease; innate

Indexed keywords

ALPHA DEFENSIN; BETA DEFENSIN; CYTOKINE; INFLAMMASOME; INTERLEUKIN 23; INTERLEUKIN 9; MUCIN; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; POLYPEPTIDE ANTIBIOTIC AGENT; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR; VASCULAR ENDOTHELIAL GROWTH INHIBITOR;

ADAPTIVE IMMUNITY; B LYMPHOCYTE; COLITIS; CROHN DISEASE; DENDRITIC CELL; EPITHELIUM; FIBROSIS; HOMEOSTASIS; HUMAN; IMMUNOREGULATION; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; LYMPHOID CELL; MACROPHAGE; MUCOSA; MUCOSAL ASSOCIATED INVARIANT T CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN POLYMORPHISM; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL; TH9 CELL; ULCERATIVE COLITIS; IMMUNOLOGY; INTESTINE MUCOSA;

ADAPTIVE IMMUNITY; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; IMMUNITY, INNATE; INTESTINAL MUCOSA;

EID: 85007039352     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000955     Document Type: Review

References (198)

1. Abraham C, Cho JH. IL-23 and autoimmunity: new insights into the pathogenesis of inflammatory bowel disease. Annu Rev Med. 2009;60: 97-110.
2. Geremia A, Biancheri P, Allan P, et al. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev. 2014;13:3-10.
3. Abreu MT, Fukata M, Arditi M. TLR signaling in the gut in health and disease. J Immunol. 2005;174:4453-4460.
4. McGuckin MA, Linden SK, Sutton P, et al. Mucin dynamics and enteric pathogens. Nat Rev Microbiol. 2011;9:265-278.
5. Wallace KL, Zheng LB, Kanazawa Y, et al. Immunopathology of inflammatory bowel disease. World J Gastroenterol. 2014;20:6-21.
6. Van der Sluis M, De Koning BAE, De Bruijn ACJM, et al. Muc2-Deficient mice spontaneously develop colitis, indicating that MUC2 is Critical for colonic protection. Gastroenterology. 2006;131:117-129.
7. Velcich A, Yang W, Heyer J, et al. Colorectal Cancer in mice genetically deficient in the mucin Muc2. Science. 2002;295:1726-1729.
8. Buisine MP, Desreumaux P, Debailleul V, et al. Abnormalities in mucin gene expression in Crohn?s disease. Inflamm Bowel Dis. 1999;5:24-32.
9. Larsson JM, Karlsson H, Crespo JG, et al. Altered O-glycosylation profile of MUC2 mucin occurs in active ulcerative colitis and is associated with increased inflammation. Inflamm Bowel Dis. 2011;17:2299-2307.
10. Salim SY, Soderholm JD. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis. 2011;17:362-381.
11. Pearson AD, Eastham EJ, Laker MF, et al. Intestinal permeability in children with Crohn?s disease and coeliac disease. Br Med J (Clin Res Ed). 1982;285:20-21.
12. Consortium UIG, Barrett JC, Lee JC, et al. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet. 2009;41:1330-1334.
13. Klag T, Stange EF, Wehkamp J. Defective antibacterial barrier in inflammatory bowel disease. Dig Dis. 2013;31:310-316.
14. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature. 2002;415:389-395.
15. Boman HG. Peptide antibiotics and their role in innate immunity. Annu Rev Immunol. 1995;13:61-92.
16. Chu H, Pazgier M, Jung G, et al. Human a-defensin 6 promotes mucosal innate immunity through self-Assembled peptide nanonets. Science. 2012;337:477-481.
17. Inohara N, Chamaillard M, McDonald C, et al. NOD-LRR proteins: Role in host-microbial Interactions and inflammatory disease. Annu Rev Biochem. 2005;74:355-383.
18. Cuthbert AP, Fisher SA, Mirza MM, et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology. 2002;122:867-874.
19. Wehkamp J, Salzman NH, Porter E, et al. Reduced Paneth cell a-defensins in ileal Crohn?s disease. Proc Natl Acad Sci U S A. 2005;102: 18129-18134.
20. Wehkamp J, Wang G, Kubler I, et al. The Paneth cell alpha-defensin deficiency of ileal Crohn?s disease is linked to Wnt/Tcf-4. J Immunol. 2007;179:3109-3118.
21. Wehkamp J, Harder J, Weichenthal M, et al. NOD2 (CARD15) mutations in Crohn?s disease are associated with diminished mucosal a-defensin expression. Gut. 2004;53:1658-1664.
22. Hampe J, Franke A, Rosenstiel P, et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet. 2007;39:207-211.
23. Kaser A, Lee A-H, Franke A, et al. XBP1 links ER Stress to intestinal Inflammation and confers genetic risk for human inflammatory bowel disease. Cell. 134:743-756.
24. Simms LA, Doecke JD, Roberts RL, et al. KCNN4 gene variant is associated with ileal Crohn?s disease in the Australian and New Zealand population. Am J Gastroenterol. 2010;105:2209-2217.
25. Wehkamp J, Harder J, Weichenthal M, et al. Inducible and constitutive beta-defensins are differentially expressed in Crohn?s disease and ulcerative colitis. Inflamm Bowel Dis. 2003;9:215-223.
26. Nuding S, Fellermann K, Wehkamp J, et al. Reduced mucosal antimicrobial activity in Crohn?s disease of the colon. Gut. 2007;56: 1240-1247.
27. Swidsinski A, Loening-Baucke V, Theissig F, et al. Comparative study of the intestinal mucus barrier in normal and inflamed colon. Gut. 2007; 56:343-350.
28. Testro AG, Visvanathan K. Toll-like receptors and their role in gastrointestinal disease. J Gastroenterol Hepatol. 2009;24:943-954.
29. Szebeni B, Veres G, Dezsofi A, et al. Increased expression of Toll-like receptor (TLR) 2 and TLR4 in the colonic mucosa of children with inflammatory bowel disease. Clin Exp Immunol. 2008;151:34-41.
30. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature. 2007;449:819-826.
31. Boyapati RK, Rossi AG, Satsangi J, et al. Gut mucosal DAMPs in IBD: from mechanisms to therapeutic implications. Mucosal Immunol. 2016.
32. Cario E. Toll-like receptors in inflammatory bowel diseases: a decade later. Inflamm Bowel Dis. 2010;16:1583-1597.
33. Shibolet O, Podolsky DK. TLRs in the Gut. IV. Negative regulation of Toll-like receptors and intestinal homeostasis: addition by subtraction. Am J Physiol Gastrointest Liver Physiol. 2007;292: G1469-G1473.
34. Kobayashi M, Kweon MN, Kuwata H, et al. Toll-like receptordependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice. J Clin Invest. 2003;111: 1297-1308.
35. Zhong Y, Kinio A, Saleh M. Functions of NOD-like receptors in human diseases. Front Immunol. 2013;4:333.
36. Hugot J-P, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn?s disease. Nature. 2001;411:599-603.
37. van Heel DA, Ghosh S, Butler M, et al. Muramyl dipeptide and toll-like receptor sensitivity in NOD2-Associated Crohn?s disease. Lancet. 2005; 365:1794-1796.
38. Adler J, Rangwalla SC, Dwamena BA, et al. The prognostic power of the NOD2 genotype for complicated Crohn?s disease: a meta-Analysis. Am J Gastroenterol. 2011;106:699-712.
39. Watanabe T, Kitani A, Murray PJ, et al. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol. 2004;5:800-808.
40. Levy M, Thaiss CA, Katz MN, et al. Inflammasomes and the microbiota-partners in the preservation of mucosal homeostasis. Semin Immunopathol. 2015;37:39-46.
41. Franchi L, Munoz-Planillo R, Nunez G. Sensing and reacting to microbes through the inflammasomes. Nat Immunol. 2012;13:325-332.
42. Opipari A, Franchi L. Role of inflammasomes in intestinal inflammation and Crohn?s disease. Inflamm Bowel Dis. 2015;21:173-181.
43. Muñoz-Planillo R, Kuffa P, Martínez-Colón G, et al. K+ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity. 38:1142-1153.
44. Bauer C, Duewell P, Mayer C, et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut. 2010;59:1192-1199.
45. Bauer C, Duewell P, Lehr HA, et al. Protective and aggravating effects of NLRP3 inflammasome activation in IBD models: influence of genetic and environmental factors. Dig Dis. 2012;30(suppl 1):82-90.
46. Schoultz I, Verma D, Halfvarsson J, et al. Combined polymorphisms in genes encoding the inflammasome components NALP3 and CARD8 confer susceptibility to Crohn?s disease in Swedish men. Am J Gastroenterol. 2009;104:1180-1188.
47. Villani A-C, Lemire M, Fortin G, et al. Common variants in the NLRP3 region contribute to Crohn?s disease susceptibility. Nat Genet. 2009;41: 71-76.
48. Lewis GJ, Massey DCO, Zhang H, et al. Genetic association between NLRP3 variants and Crohn?s disease does not replicate in a large UK panel. Inflamm Bowel Dis. 2011;17:1387-1391.
49. Coccia M, Harrison OJ, Schiering C, et al. IL-1b mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4+ Th17 cells. J Exp Med. 2012;209: 1595-1609.
50. Chuang SY, Yang CH, Chou CC, et al. TLR-induced PAI-2 expression suppresses IL-1beta processing via increasing autophagy and NLRP3 degradation. Proc Natl Acad Sci U S A. 2013;110:16079-16084.
51. Plantinga TS, Crisan TO, Oosting M, et al. Crohn?s diseaseassociated ATG16L1 polymorphism modulates pro-inflammatory cytokine responses selectively upon activation of NOD2. Gut. 2011;60:1229-1235.
52. Plantinga TS, Joosten LA, Netea MG. ATG16L1 polymorphisms are associated with NOD2-induced hyperinflammation. Autophagy. 2011; 7:1074-1075.
53. Hu B, Elinav E, Huber S, et al. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc Natl Acad Sci U S A. 2010;107:21635-21640.
54. Kofoed EM, Vance RE. Innate immune recognition of bacterial ligands by NAIPs determines inflammasome specificity. Nature. 2011;477: 592-595.
55. Zhao Y, Yang J, Shi J, et al. The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. Nature. 2011;477: 596-600.
56. Mariathasan S, Newton K, Monack DM, et al. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature. 2004; 430:213-218.
57. Franchi L, Stoolman J, Kanneganti T-D, et al. Critical role for Ipaf in Pseudomonas aeruginosa-induced caspase-1 activation. Eur J Immunol. 2007;37:3030-3039.
58. Elinav E, Strowig T, Kau AL, et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell. 2011;145:745-757.
59. Normand S, Delanoye-Crespin A, Bressenot A, et al. Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial selfrenewal and colorectal carcinogenesis upon injury. Proc Natl Acad Sci U S A. 2011;108:9601-9606.
60. Elinav E, Nowarski R, Thaiss CA, et al. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13:759-771.
61. Goldberg R, Prescott N, Lord GM, et al. The unusual suspects-innate lymphoid cells as novel therapeutic targets in IBD. Nat Rev Gastroenterol Hepatol. 2015;12:271-283.
62. Spits H, Artis D, Colonna M, et al. Innate lymphoid cells-A proposal for uniform nomenclature. Nat Rev Immunol. 2013;13:145-149.
63. Bernink JH. Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nat Immunol. 2013;14:221-229.
64. Fuchs A. Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12-and IL-15-responsive IFN-gamma-producing cells. Immunity. 2013;38:769-781.
65. Buonocore S. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature. 2010;464:1371-1375.
66. Tilloy F, Treiner E, Park SH, et al. An invariant T cell receptor alpha chain defines a novel TAP-independent major histocompatibility complex class Ib-restricted alpha/beta T cell subpopulation in mammals. J Exp Med. 1999;189:1907-1921.
67. Treiner E, Duban L, Moura IC, et al. Mucosal-Associated invariant T (MAIT) cells: an evolutionarily conserved T cell subset. Microbes Infect. 2005;7:552-559.
68. Corbett AJ, Eckle SB, Birkinshaw RW, et al. T-cell activation by transitory neo-Antigens derived from distinct microbial pathways. Nature. 2014;509:361-365.
69. Kjer-Nielsen L, Patel O, Corbett AJ, et al. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature. 2012;491:717-723.
70. Le Bourhis L, Martin E, Peguillet I, et al. Antimicrobial activity of mucosal-Associated invariant T cells. Nat Immunol. 2010;11:701-708.
71. Georgel P, Radosavljevic M, Macquin C, et al. The non-conventional MHC class I MR1 molecule controls infection by Klebsiella pneumoniae in mice. Mol Immunol. 2011;48:769-775.
72. Nauciel C, Espinasse-Maes F. Role of gamma interferon and tumor necrosis factor alpha in resistance to salmonella typhimurium infection. Infect Immun. 1992;60:450-454.
73. Reantragoon R, Corbett AJ, Sakala IG, et al. Antigen-loaded MR1 tetramers define T cell receptor heterogeneity in mucosal-Associated invariant T cells. J Exp Med. 2013;210:2305-2320.
74. Haga K, Chiba A, Shibuya T, et al. MAIT cells are activated and accumulated in the inflamed mucosa of ulcerative colitis. J Gastroenterol Hepatol. 2015.
75. Serriari NE, Eoche M, Lamotte L, et al. Innate mucosal-Associated invariant T (MAIT) cells are activated in inflammatory bowel diseases. Clin Exp Immunol. 2014;176:266-274.
76. Sugimoto K, Ogawa A, Mizoguchi E, et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest. 2008; 118:534-544.
77. Hiejima E, Kawai T, Nakase H, et al. Reduced numbers and proapoptotic features of mucosal-Associated invariant T cells as a characteristic finding in patients with IBD. Inflamm Bowel Dis. 2015.
78. Voedisch S, Koenecke C, David S, et al. Mesenteric lymph nodes confine dendritic cell-mediated dissemination of Salmonella enterica serovar Typhimurium and limit systemic disease in mice. Infect Immun. 2009;77: 3170-3180.
79. Coombes JL, Siddiqui KR, Arancibia-Carcamo CV, et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med. 2007;204:1757-1764.
80. Johansson-Lindbom B, Svensson M, Pabst O, et al. Functional specialization of gut CD103+ dendritic cells in the regulation of tissue-selective T cell homing. J Exp Med. 2005;202:1063-1073.
81. Matteoli G, Mazzini E, Iliev ID, et al. Gut CD103+ dendritic cells express indoleamine 2, 3-dioxygenase which influences T regulatory/T effector cell balance and oral tolerance induction. Gut. 2010;59:595-604.
82. Stagg AJ, Kamm MA, Knight SC. Intestinal dendritic cells increase T cell expression of alpha4beta7 integrin. Eur J Immunol. 2002;32: 1445-1454.
83. Krajina T, Leithauser F, Moller P, et al. Colonic lamina propria dendritic cells in mice with CD4+ T cell-induced colitis. Eur J Immunol. 2003;33: 1073-1083.
84. Malmstrom V, Shipton D, Singh B, et al. CD134L expression on dendritic cells in the mesenteric lymph nodes drives colitis in T cell-restored SCID mice. J Immunol. 2001;166:6972-6981.
85. te Velde AA, van Kooyk Y, Braat H, et al. Increased expression of DCSIGN+IL-12+IL-18+ and CD83+IL-12-IL-18-dendritic cell populations in the colonic mucosa of patients with Crohn?s disease. Eur J Immunol. 2003;33:143-151.
86. Platt AM, Mowat AM. Mucosal macrophages and the regulation of immune responses in the intestine. Immunol Lett. 2008;119:22-31.
87. Smith PD, Smythies LE, Shen R, et al. Intestinal macrophages and response to microbial encroachment. Mucosal Immunol. 2011;4:31-42.
88. Denning TL, Wang YC, Patel SR, et al. Lamina propria macrophages and dendritic cells differentially induce regulatory and interleukin 17-producing T cell responses. Nat Immunol. 2007;8: 1086-1094.
89. Lin HH, Faunce DE, Stacey M, et al. The macrophage F4/80 receptor is required for the induction of antigen-specific efferent regulatory T cells in peripheral tolerance. J Exp Med. 2005;201:1615-1625.
90. Kamada N. Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis. J Clin Invest. 2008;118:2269-2280.
91. Hausmann M, Kiessling S, Mestermann S, et al. Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation. Gastroenterology. 2002;122:1987-2000.
92. Cerutti A, Rescigno M. The biology of intestinal immunoglobulin A responses. Immunity. 2008;28:740-750.
93. Cerutti A. The regulation of IgA class switching. Nat Rev Immunol. 2008;8:421-434.
94. Kaetzel CS. The polymeric immunoglobulin receptor: bridging innate and adaptive immune responses at mucosal surfaces. Immunological Rev. 2005;206:83-99.
95. Pabst O. New concepts in the generation and functions of IgA. Nat Rev Immunol. 2012;12:821-832.
96. Alexander KL, Targan SR, Elson CO III, Microbiota activation and regulation of innate and adaptive immunity. Immunol Rev. 2014. 260: 206-220.
97. Batista FD, Harwood NE. The who, how and where of antigen presentation to B cells. Nat Rev Immunol. 2009;9:15-27.
98. Amu S, Saunders SP, Kronenberg M, et al. Regulatory B cells prevent and reverse allergic airway inflammation via FoxP3-positive T regulatory cells in a murine model. J Allergy Clin Immunol. 2010. 125: 1114-1124.e8.
99. Tadmor T, Zhang Y, Cho HM, et al. The absence of B lymphocytes reduces the number and function of T-regulatory cells and enhances the anti-Tumor response in a murine tumor model. Cancer Immunol Immunother. 2011;60:609-619.
100. Fillatreau S, Sweenie CH, McGeachy MJ, et al. B cells regulate autoimmunity by provision of IL-10. Nat Immunol. 2002;3:944-950.
101. Lee JH, Noh J, Noh G, et al. Allergen-specific transforming growth factor-beta-producing CD19+CD5+ regulatory B-cell (Br3) responses in human late eczematous allergic reactions to cow?s milk. J Interferon Cytokine Res. 2011;31:441-449.
102. Liu ZQ, Wu Y, Song JP, et al. Tolerogenic CX3CR1+ B cells suppress food allergy-induced intestinal inflammation in mice. Allergy. 2013;68: 1241-1248.
103. Polese L, Boetto R, De Franchis G, et al. B1a lymphocytes in the rectal mucosa of ulcerative colitis patients. World J Gastroenterol. 2012;18: 144-149.
104. Lin Z, Hegarty JP, Yu W, et al. Identification of disease-Associated DNA methylation in B cells from Crohn?s disease and ulcerative colitis patients. Dig Dis Sci. 2012;57:3145-3153.
105. Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol. 1994;12:227-257.
106. Monteleone G, Biancone L, Marasco R, et al. Interleukin 12 is expressed and actively released by Crohn?s disease intestinal lamina propria mononuclear cells. Gastroenterology. 112:1169-1178.
107. Monteleone G, Trapasso F, Parrello T, et al. Bioactive IL-18 expression is up-regulated in Crohn?s disease. J Immunol. 1999;163:143-147.
108. Di Sabatino A, Biancheri P, Rovedatti L, et al. New pathogenic paradigms in inflammatory bowel disease. Inflamm Bowel Dis. 2012; 18:368-371.
109. Breese E, Braegger CP, Corrigan CJ, et al. Interleukin-2-and interferongamma-secreting T cells in normal and diseased human intestinal mucosa. Immunology. 1993;78:127-131.
110. Fuss IJ, Heller F, Boirivant M, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest. 2004;113:1490-1497.
111. Biancheri P, Di Sabatino A, Corazza G, et al. Proteases and the gut barrier. Cell Tissue Res. 2013;351:269-280.
112. Kugathasan S, Saubermann LJ, Smith L, et al. Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. Gut. 2007;56:1696-1705.
113. Gerlach K, Hwang Y, Nikolaev A, et al. TH9 cells that express the transcription factor PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells. Nat Immunol. 2014;15:676-686.
114. Uyttenhove C, Simpson RJ, Van Snick J. Functional and structural characterization of P40, a mouse glycoprotein with T-cell growth factor activity. Proc Natl Acad Sci U S A. 1988;85:6934-6938.
115. Neurath MF, Finotto S. IL-9 signaling as key driver of chronic inflammation in mucosal immunity. Cytokine Growth Factor Rev. 2016.
116. Kaplan MH. Th9 cells: differentiation and disease. Immunological Rev. 2013;252:104-115.
117. Barlow JL, McKenzie AN. Type-2 innate lymphoid cells in human allergic disease. Curr Opin Allergy Clin Immunol. 2014;14:397-403.
118. Abdelilah S, Latifa K, Esra N, et al. Functional expression of IL-9 receptor by human neutrophils from asthmatic donors: role in IL-8 release. J Immunol. 2001;166:2768-2774.
119. Shimbara A, Christodoulopoulos P, Soussi-Gounni A, et al. IL-9 and its receptor in allergic and nonallergic lung disease: increased expression in asthma. J Allergy Clin Immunol. 2000;105(1 pt 1):108-115.
120. Stassen M, Arnold M, Hultner L, et al. Murine bone marrow-derived mast cells as potent producers of IL-9: costimulatory function of IL-10 and kit ligand in the presence of IL-1. J Immunol. 2000;164:5549-5555.
121. Veldhoen M, Uyttenhove C, van Snick J, et al. Transforming growth factor-beta ?reprograms? the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol. 2008;9: 1341-1346.
122. Tamiya T, Ichiyama K, Kotani H, et al. Smad2/3 and IRF4 play a cooperative role in IL-9-producing T cell induction. J Immunol. 2013;191: 2360-2371.
123. Chang HC, Sehra S, Goswami R, et al. The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation. Nat Immunol. 2010;11:527-534.
124. Zhu YX, Kang LY, Luo W, et al. Multiple transcription factors are required for activation of human interleukin 9 gene in T cells. J Biol Chem. 1996;271:15815-15822.
125. Goswami R, Jabeen R, Yagi R, et al. STAT6-dependent regulation of Th9 development. J Immunol. 2012;188:968-975.
126. Nalleweg N, Chiriac MT, Podstawa E, et al. IL-9 and its receptor are predominantly involved in the pathogenesis of UC. Gut. 2015;64: 743-755.
127. Neubauer K, Krzystek-Korpacka M, M M, et al. P042. Circulating IL9 in inflammatory bowel disease: possible marker of mucosal non-healing. J Crohn?s Colitis. 2016;10(suppl 1):S110-S111.
128. Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6:1123-1132.
129. Zhou L, Ivanov II, Spolski R, et al. IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007;8:967-974.
130. Ueno A, Ghosh A, Hung D, et al. Th17 plasticity and its changes associated with inflammatory bowel disease. World J Gastroenterol. 2015; 21:12283-12295.
131. Sarra M, Pallone F, Macdonald TT, et al. IL-23/IL-17 axis in IBD. Inflamm Bowel Dis. 2010;16:1808-1813.
132. Ivanov II, Frutos Rde L, Manel N, et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe. 2008;4:337-349.
133. Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-Analysis increases to 71 the number of confirmed Crohn?s disease susceptibility loci. Nat Genet. 2010;42:1118-1125.
134. Kobayashi T, Okamoto S, Hisamatsu T, et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn?s disease. Gut. 2008;57:1682-1689.
135. Rovedatti L, Kudo T, Biancheri P, et al. Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut. 2009;58:1629-1636.
136. Olsen T, Rismo R, Cui G, et al. TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation. Cytokine. 2011;56:633-640.
137. Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cellmediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest. 2006;116:1310-1316.
138. Elson CO, Cong Y, Weaver CT, et al. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology. 2007;132:2359-2370.
139. Zhang Z, Zheng M, Bindas J, et al. Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm Bowel Dis. 2006;12: 382-388.
140. Moseley TA, Haudenschild DR, Rose L, et al. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev. 2003;14:155-174.
141. O?Connor W Jr, Kamanaka M, Booth CJ, et al. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol. 2009;10:603-609.
142. Awasthi A, Kuchroo VK. IL-17A directly inhibits TH1 cells and thereby suppresses development of intestinal inflammation. Nat Immunol. 2009; 10:568-570.
143. Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn?s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61:1693-1700.
144. Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-To-severe Crohn?s disease. Gastroenterology. 2008;135:1130-1141.
145. Sandborn W, Feagan BG, Gasink C, et al. 768 a phase 3 randomized, multicenter, double-blind, placebo-controlled study of ustekinumab maintenance therapy in moderate-severe Crohn?s disease patients: results from IM-UNITI. Gastroenterology. 150:S157-S158.
146. Mayne CG, Williams CB. Induced and natural regulatory T cells in the development of inflammatory bowel disease. Inflamm Bowel Dis. 2013; 19:1772-1788.
147. Haribhai D, Williams JB, Jia S, et al. A requisite role for induced regulatory T cells in tolerance based on expanding antigen receptor diversity. Immunity. 2011;35:109-122.
148. Caudy AA, Reddy ST, Chatila T, et al. CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes. J Allergy Clin Immunol. 2007;119:482-487.
149. Barnes MJ, Powrie F. Regulatory T cells reinforce intestinal homeostasis. Immunity. 2009;31:401-411.
150. Bilate AB, Lafaille JJ. It takes two to tango. Immunity. 2011;35:6-8.
151. Chen W, Jin W, Hardegen N, et al. Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003;198:1875-1886.
152. Atarashi K, Umesaki Y, Honda K. Microbiotal influence on T cell subset development. Semin Immunol. 2011;23:146-153.
153. Tanoue T, Honda K. Induction of Treg cells in the mouse colonic mucosa: a central mechanism to maintain host-microbiota homeostasis. Semin Immunol. 2012;24:50-57.
154. O?Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med. 2004;10:801-805.
155. Chen W, Frank ME, Jin W, et al. TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity. 2001;14: 715-725.
156. Izcue A, Coombes JL, Powrie F. Regulatory lymphocytes and intestinal inflammation. Annu Rev Immunol. 2009;27:313-338.
157. Monteleone G, Kumberova A, Croft NM, et al. Blocking Smad7 restores TGF-b1 signaling in chronic inflammatory bowel disease. J Clin Invest. 2001;108:601-609.
158. Monteleone G, Neurath MF, Ardizzone S, et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn?s disease. New Engl J Med. 2015;372:1104-1113.
159. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993;75:263-274.
160. Hagenbaugh A, Sharma S, Dubinett SM, et al. Altered immune responses in interleukin 10 transgenic mice. J Exp Med. 1997;185: 2101-2110.
161. Powrie F, Leach MW, Mauze S, et al. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity. 1994;1:553-562.
162. Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science. 2000;289: 1352-1355.
163. Franke A, Balschun T, Karlsen TH, et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet. 2008;40:1319-1323.
164. Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009;361: 2033-2045.
165. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med. 1998;188:287-296.
166. Grossman WJ, Verbsky JW, Barchet W, et al. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity. 2004;21:589-601.
167. Zhao DM, Thornton AM, DiPaolo RJ, et al. Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood. 2006;107:3925-3932.
168. Onishi Y, Fehervari Z, Yamaguchi T, et al. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci U S A. 2008;105: 10113-10118.
169. Johnston RL, Lutzky J, Chodhry A, et al. Cytotoxic T-lymphocyte-Associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci. 2009;54:2538-2540.
170. Buckner JH. Mechanisms of impaired regulation by CD4(+)CD25(+) FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol. 2010;10:849-859.
171. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4:330-336.
172. Powrie F, Leach MW, Mauze S, et al. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol. 1993;5:1461-1471.
173. Lee YK, Mukasa R, Hatton RD, et al. Developmental plasticity of Th17 and Treg cells. Curr Opin Immunol. 2009;21:274-280.
174. Yates J, Rovis F, Mitchell P, et al. The maintenance of human CD4+CD25+ regulatory T cell function: IL-2, IL-4, IL-7 and IL-15 preserve optimal suppressive potency in vitro. Int Immunol. 2007;19: 785-799.
175. Chamouard P, Monneaux F, Richert Z, et al. Diminution of circulating CD4+CD25high T cells in naïve Crohn?s disease. Dig Dis Sci. 2009;54: 2084-2093.
176. Maul J, Loddenkemper C, Mundt P, et al. Peripheral and intestinal regulatory CD4+CD25high T cells in inflammatory bowel disease. Gastroenterology.128:1868-1878.
177. Holmen N, Lundgren A, Lundin S, et al. Functional CD4+CD25high regulatory T cells are enriched in the colonic mucosa of patients with active ulcerative colitis and increase with disease activity. Inflamm Bowel Dis. 2006;12:447-456.
178. Koenen HJ, Smeets RL, Vink PM, et al. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood. 2008; 112:2340-2352.
179. Boirivant M, Pallone F, Di Giacinto C, et al. Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis. Gastroenterology. 2006;131:1786-1798.
180. Tan KB, Harrop J, Reddy M, et al. Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene. 1997;204:35-46.
181. Prehn JL, Mehdizadeh S, Landers CJ, et al. Potential role for TL1A, the new TNF-family member and potent costimulator of IFN-gamma, in mucosal inflammation. Clin Immunol. 2004;112:66-77.
182. Bamias G, Martin C, Marini M, et al. Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. J Immunol. 2003;171:4868-4874.
183. Siakavellas SI, Bamias G. Tumor necrosis factor-like cytokine TL1A and its receptors DR3 and DcR3: important new factors in mucosal homeostasis and inflammation. Inflamm Bowel Dis. 2015.
184. Lu Y, Gu X, Chen L, et al. Interferon-gamma produced by tumorinfiltrating NK cells and CD4+ T cells downregulates TNFSF15 expression in vascular endothelial cells. Angiogenesis. 2014;17:529-540.
185. Saruta M, Michelsen KS, Thomas LS, et al. TLR8-mediated activation of human monocytes inhibits TL1A expression. Eur J Immunol. 2009;39: 2195-2202.
186. Taraban VY, Slebioda TJ, Willoughby JE, et al. Sustained TL1A expression modulates effector and regulatory T-cell responses and drives intestinal goblet cell hyperplasia. Mucosal Immunol. 2011;4:186-196.
187. Khan SQ, Tsai MS, Schreiber TH, et al. Cloning, expression, and functional characterization of TL1A-Ig. J Immunol. 2013;190:1540-1550.
188. Cleynen I, Gonzalez JR, Figueroa C, et al. Genetic factors conferring an increased susceptibility to develop Crohn?s disease also influence disease phenotype: results from the IBDchip European Project. Gut. 2013;62: 1556-1565.
189. Yang DH, Yang SK, Song K, et al. TNFSF15 is an independent predictor for the development of Crohn?s disease-related complications in Koreans. J Crohns Colitis. 2014;8:1315-1326.
190. Haritunians T, Taylor KD, Targan SR, et al. Genetic predictors of medically refractory ulcerative colitis. Inflamm Bowel Dis. 2010;16:1830-1840.
191. Meylan F, Song YJ, Fuss I, et al. The TNF-family cytokine TL1A drives IL-13-dependent small intestinal inflammation. Mucosal Immunol. 2011; 4:172-185.
192. Takedatsu H, Michelsen KS, Wei B, et al. TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and Thelper 17 activation. Gastroenterology. 2008;135:552-567.
193. Pappu BP, Borodovsky A, Zheng TS, et al. TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease. J Exp Med. 2008;205:1049-1062.
194. Tougaard P, Skov S, Pedersen AE, et al. TL1A regulates TCRgammadelta+intraepithelial lymphocytes and gut microbial composition. Eur J Immunol. 2015;45:865-875.
195. Shih DQ, Barrett R, Zhang X, et al. Constitutive TL1A (TNFSF15) expression on lymphoid or myeloid cells leads to mild intestinal inflammation and fibrosis. PLoS One. 2011;6:e16090.
196. Zheng L, Zhang X, Chen J, et al. Sustained TL1A expression on both lymphoid and myeloid cells leads to MILD spontaneous intestinal inflammation and fibrosis. Eur J Microbiol Immunol (Bp). 2013;3: 11-20.
197. Barrett R, Zhang X, Koon HW, et al. Constitutive TL1A expression under colitogenic conditions modulates the severity and location of gut mucosal inflammation and induces s. Am J Pathol. 2012;180: 636-649.
198. Shih DQ, Zheng L, Zhang X, et al. Inhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis. Mucosal Immunol. 2014;7: 1492-1503.